Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 23 03:06PM ET
12.19
Dollar change
+0.28
Percentage change
2.38
%
IndexRUT P/E- EPS (ttm)-12.62 Insider Own4.95% Shs Outstand21.00M Perf Week16.13%
Market Cap256.07M Forward P/E- EPS next Y-8.68 Insider Trans92.68% Shs Float19.96M Perf Month64.34%
Income-239.61M PEG- EPS next Q-1.64 Inst Own49.77% Short Float16.22% Perf Quarter-10.61%
Sales161.42M P/S1.59 EPS this Y35.33% Inst Trans- Short Ratio4.40 Perf Half Y-10.47%
Book/sh-9.59 P/B- EPS next Y2.78% ROA-71.52% Short Interest3.24M Perf Year-59.89%
Cash/sh2.52 P/C4.84 EPS next 5Y- ROE- 52W Range4.78 - 42.60 Perf YTD-26.36%
Dividend Est.- P/FCF- EPS past 5Y13.79% ROI- 52W High-71.38% Beta1.27
Dividend TTM- Quick Ratio0.24 Sales past 5Y98.93% Gross Margin90.51% 52W Low155.37% ATR (14)1.26
Dividend Ex-Date- Current Ratio0.24 EPS Y/Y TTM22.36% Oper. Margin-85.64% RSI (14)58.86 Volatility9.19% 13.88%
Employees389 Debt/Eq- Sales Y/Y TTM69.94% Profit Margin-148.44% Recom1.20 Target Price44.25
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q29.41% Payout- Rel Volume0.74 Prev Close11.91
Sales Surprise-40.63% EPS Surprise5.20% Sales Q/Q22.28% EarningsMay 07 BMO Avg Volume736.56K Price12.19
SMA206.03% SMA5019.17% SMA200-24.03% Trades Volume470,461 Change2.38%
Date Action Analyst Rating Change Price Target Change
Jun-06-23Initiated Robert W. Baird Outperform $8
Jun-06-23Initiated Robert W. Baird Outperform $60 → $80
Feb-28-23Resumed H.C. Wainwright Buy $8
Sep-28-22Initiated SMBC Nikko Outperform $5
Dec-16-21Initiated H.C. Wainwright Buy $12
Nov-19-19Resumed B. Riley FBR Buy $6
Apr-22-19Initiated B. Riley FBR Buy
Oct-28-16Downgrade H.C. Wainwright Buy → Neutral $10 → $5
Oct-27-16Reiterated Maxim Group Buy
Mar-11-16Upgrade Maxim Group Hold → Buy $7
Today 07:30AM
May-22-24 07:30AM
May-16-24 07:30AM
May-08-24 01:22PM
11:11AM
03:09AM Loading…
03:09AM
May-07-24 05:45PM
01:52PM
12:24PM
09:00AM
08:56AM
07:59AM
07:40AM
07:30AM
May-01-24 07:30AM
08:30AM Loading…
Apr-28-24 08:30AM
Apr-24-24 10:00AM
Apr-23-24 07:30AM
Apr-22-24 04:17AM
Apr-12-24 07:30AM
Apr-08-24 03:34AM
Apr-05-24 04:30PM
Apr-03-24 04:19AM
Mar-24-24 04:05PM
Mar-22-24 01:25PM
Mar-15-24 02:11PM
Mar-14-24 01:30PM
08:51AM
07:39AM
07:30AM
07:30AM Loading…
Mar-06-24 07:30AM
Mar-05-24 04:30PM
Feb-29-24 07:30AM
Feb-26-24 07:30AM
Feb-15-24 06:38PM
07:02AM
Feb-01-24 07:09PM
Jan-31-24 07:30AM
Jan-26-24 03:57PM
Jan-22-24 07:30AM
Jan-05-24 04:30PM
Jan-04-24 07:30AM
Dec-24-23 09:45AM
Dec-20-23 07:30AM
Dec-11-23 07:30AM
Nov-07-23 06:55AM
06:41AM
06:30AM
Oct-26-23 09:05AM
Oct-22-23 12:00PM
Oct-21-23 04:15AM
Oct-10-23 07:30AM
Oct-05-23 07:30AM
Sep-01-23 04:30PM
Aug-28-23 08:30AM
07:30AM
Aug-24-23 09:54AM
Aug-23-23 02:00PM
01:16PM
08:00AM
Aug-18-23 04:27AM
Aug-17-23 10:04AM
Aug-09-23 08:30AM
Aug-08-23 10:00AM
08:19AM
07:30AM
Aug-03-23 05:25PM
Jul-28-23 07:30AM
Jul-26-23 07:30AM
Jul-20-23 07:30AM
Jul-10-23 07:58AM
Jun-30-23 11:15AM
Jun-26-23 10:15AM
Jun-06-23 07:46AM
Jun-05-23 09:49AM
07:30AM
May-25-23 07:30AM
May-10-23 06:11AM
May-09-23 07:00PM
09:15AM
08:10AM
08:00AM
May-03-23 09:08AM
Apr-26-23 10:35AM
Apr-25-23 07:30AM
Apr-24-23 07:30AM
Apr-18-23 11:20AM
Apr-17-23 01:55PM
08:47AM
07:30AM
Apr-12-23 04:30PM
Apr-04-23 03:53PM
Mar-30-23 08:41AM
Mar-27-23 03:12PM
09:45AM
Mar-23-23 12:21PM
Mar-17-23 04:31AM
Mar-14-23 04:00PM
08:45AM
07:30AM
Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ARMEN GARO HSee RemarksFeb 15 '24Buy0.65500,000324,050625,969Feb 15 06:59 PM
WIINBERG ULFDirectorNov 15 '23Buy0.7625,00019,000124,063Nov 17 04:22 PM
AGENUS INC10% OwnerOct 16 '23Buy1.1042947221,772,863Oct 16 05:49 PM
AGENUS INC10% OwnerOct 13 '23Buy1.1019,37321,31021,772,434Oct 16 05:49 PM
AGENUS INC10% OwnerOct 12 '23Buy1.103,1733,48821,753,061Oct 16 05:49 PM
AGENUS INC10% OwnerOct 04 '23Buy1.0915,00116,38021,749,888Oct 06 04:26 PM
AGENUS INC10% OwnerAug 29 '23Buy1.5229,67845,01621,734,887Aug 31 05:53 PM
AGENUS INC10% OwnerAug 28 '23Buy1.4512,80818,57021,705,209Aug 28 05:15 PM
AGENUS INC10% OwnerAug 24 '23Buy1.54170,244262,90821,692,401Aug 28 05:15 PM
Last Close
May 23 03:04PM ET
0.9876
Dollar change
-0.0124
Percentage change
-1.24
%
INKT MiNK Therapeutics Inc daily Stock Chart
Index- P/E- EPS (ttm)-0.60 Insider Own71.34% Shs Outstand34.60M Perf Week-5.04%
Market Cap34.30M Forward P/E- EPS next Y-0.44 Insider Trans0.00% Shs Float9.95M Perf Month11.09%
Income-20.59M PEG- EPS next Q-0.10 Inst Own2.70% Short Float0.88% Perf Quarter9.73%
Sales0.00M P/S- EPS this Y37.95% Inst Trans32.08% Short Ratio0.47 Perf Half Y-5.04%
Book/sh-0.59 P/B- EPS next Y-8.26% ROA-175.32% Short Interest0.09M Perf Year-54.28%
Cash/sh0.17 P/C5.89 EPS next 5Y- ROE-1238.95% 52W Range0.75 - 3.34 Perf YTD-7.71%
Dividend Est.- P/FCF- EPS past 5Y2.37% ROI- 52W High-70.43% Beta0.07
Dividend TTM- Quick Ratio0.54 Sales past 5Y-25.00% Gross Margin- 52W Low31.67% ATR (14)0.09
Dividend Ex-Date- Current Ratio0.54 EPS Y/Y TTM22.20% Oper. Margin0.00% RSI (14)50.92 Volatility7.33% 9.01%
Employees31 Debt/Eq- Sales Y/Y TTM- Profit Margin- Recom1.33 Target Price8.50
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q34.23% Payout- Rel Volume0.53 Prev Close1.00
Sales Surprise- EPS Surprise27.87% Sales Q/Q- EarningsMay 14 BMO Avg Volume187.54K Price0.99
SMA201.65% SMA502.04% SMA200-8.66% Trades Volume86,889 Change-1.24%
May-22-24 07:30AM
May-15-24 03:04AM
May-14-24 11:52AM
07:30AM
May-13-24 07:30AM
07:30AM Loading…
Apr-30-24 07:30AM
Apr-08-24 12:00PM
Mar-25-24 12:00PM
Mar-22-24 01:25PM
Mar-21-24 11:06PM
11:53AM
07:00AM
Mar-07-24 07:30AM
Mar-06-24 08:30AM
Feb-14-24 08:00AM
08:00AM Loading…
Feb-06-24 08:00AM
Jan-30-24 08:00AM
Dec-20-23 07:30AM
Nov-09-23 08:05AM
07:00AM
Nov-03-23 12:00PM
Oct-30-23 08:00AM
Sep-27-23 09:05AM
Aug-24-23 08:30AM
Aug-10-23 07:30AM
Jul-28-23 08:30AM
Jun-05-23 07:30AM
May-22-23 08:30AM
May-18-23 08:30AM
May-11-23 08:00AM
08:30AM Loading…
Apr-27-23 08:30AM
Apr-18-23 01:32PM
Apr-16-23 08:03AM
Apr-04-23 09:55AM
Mar-30-23 08:41AM
Mar-29-23 12:00PM
Mar-24-23 07:36AM
Mar-21-23 08:00AM
Mar-15-23 08:45AM
Mar-07-23 09:00AM
Feb-16-23 09:28AM
Jan-11-23 02:25PM
Dec-22-22 10:49AM
Nov-17-22 09:00AM
Nov-10-22 09:05AM
Nov-06-22 09:39AM
Nov-03-22 08:00AM
Oct-20-22 09:00AM
Oct-05-22 09:16AM
08:30AM
Aug-31-22 09:00AM
Aug-16-22 06:16AM
Aug-09-22 08:00AM
Aug-02-22 08:30AM
Jul-27-22 08:30AM
May-25-22 08:30AM
May-10-22 08:00AM
May-09-22 08:43AM
Apr-27-22 05:19PM
Mar-18-22 08:30AM
Mar-03-22 04:35PM
09:28AM
Mar-01-22 08:00AM
Jan-15-22 07:47AM
Jan-12-22 09:41AM
Nov-17-21 04:15PM
Nov-12-21 07:30PM
07:00AM
Nov-09-21 08:00AM
08:00AM
Oct-19-21 04:25PM
Oct-15-21 05:31PM
Oct-14-21 08:29PM
MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company was founded in 2017 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
AGENUS INC10% OwnerOct 16 '23Buy1.1042947221,772,863Oct 16 05:49 PM
AGENUS INC10% OwnerOct 13 '23Buy1.1019,37321,31021,772,434Oct 16 05:49 PM
AGENUS INC10% OwnerOct 12 '23Buy1.103,1733,48821,753,061Oct 16 05:49 PM
AGENUS INC10% OwnerOct 04 '23Buy1.0915,00116,38021,749,888Oct 06 04:26 PM
AGENUS INC10% OwnerAug 29 '23Buy1.5229,67845,01621,734,887Aug 31 05:53 PM
AGENUS INC10% OwnerAug 28 '23Buy1.4512,80818,57021,705,209Aug 28 05:15 PM
AGENUS INC10% OwnerAug 24 '23Buy1.54170,244262,90821,692,401Aug 28 05:15 PM